Effect Evaluation of Concise Intervention and Group Chain Management on Dyslipidemia in General Clinics

doi:10.12114/j.issn.1007-9572.2018.31.022

Abstract

Abstract: Objective　To evaluate the effectiveness of concise intervention combined with group chain management on dyslipidemia in general clinics.Methods　A total of 203 patients with abnormal blood lipid levelvisited Dinghai Community Health Service Center，Yangpu district of Shanghai from April to June 2017 were selected and randomly divided into control group （n=102）and intervention group（n=101）.Subjects were further divided into very-high-risk，high-risk，intermediate-risk and low-risk groups according to different cardiovascular risk factors.The intervention group was treated with concise intervention and group chain administration for six months，whereas the control group received routine clinical treatment and community management.Lipid level and control rate were compared between two groups.Results　There were no significant differences between levels of serum total cholesterol（TC），triacylglycerol（TG），low density lipoprotein cholesterol（LDL-C），and high density lipoprotein cholesterol（HDL-C） before intervention.After intervention，levels of TC，TG and LDL-C in intervention group were significantly lower than those in control group（P<0.05），and there was no significant difference in HDL-C between the two groups（P>0.05）.Control rate of LDL-C in intervention group was significantly higher than that of control group（P<0.05） after intervention，while there was no significant difference before （P>0.05）.Before intervention，there was no significant difference in control rate of LDL-C between low-risk，intermediate-risk，high-risk and very-high-risk subgroups in control group and intervention group（P>0.05）．After intervention，control rate of LDL-C in high-risk and very-high-risk groups of intervention group were significantly higher than that in the same subgroups of control group（P<0.05）.There was no significant difference in the control rate of LDL-C between low-risk and intermediate-risk subgroups（P>0.05）.Conclusion　Our research proposes the mode of combining general clinical concise intervention and group chain management，which can improve the management of blood lipid level and facilitate the control rate of LDL-C in patients with dyslipidemia.

Key words: Dyslipidemia, Control rate, Concise intervention, General clinic

摘要： 目的　探讨全科门诊简洁干预联合团队链式管理对血脂异常的干预效果。方法　选取2017年4—6月于上海市杨浦区定海社区卫生服务中心全科门诊就诊的血脂异常患者203例为研究对象，随机分为对照组（n=102）和干预组（n=101），并根据心血管危险分层将两组患者分别分为低危、中危、高危、极高危亚组。对照组进行常规门诊和社区管理，干预组行全科门诊简洁干预联合团队链式管理。干预时间均为6个月。比较干预前后两组患者血脂水平和达标率。结果　干预前，对照组和干预组血清总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）比较，差异无统计学意义（P>0.05）。干预后，干预组TC、TG、LDL-C水平低于对照组，差异有统计学意义（P<0.05）；两组HDL-C比较，差异无统计学意义（P>0.05）。干预前，对照组和干预组LDL-C达标率比较，差异无统计学意义（P>0.05）；干预后，干预组LDL-C达标率高于对照组，差异有统计学意义（P<0.05）。干预前，对照组和干预组低危、中危、高危、极高危4个亚组患者LDL-C达标率比较，差异无统计学意义（P>0.05）。干预后，干预组高危、极高危亚组患者LDL-C达标率高于对照组，差异有统计学意义（P<0.05）；低危、中危亚组患者LDL-C达标率比较，差异无统计学意义（P>0.05）。结论　全科门诊简洁干预联合团队链式管理可改善血脂异常患者的血脂管理效果，提高血脂异常患者的LDL-C达标率。

关键词: 血脂异常, 达标率, 简洁干预, 全科门诊

MA Jia,ZHU Weihong,LIU Wenbin, et al. Effect Evaluation of Concise Intervention and Group Chain Management on Dyslipidemia in General Clinics[J]. Chinese General Practice, 2018, 21(31): 3882-3885. DOI: 10.12114/j.issn.1007-9572.2018.31.022.
马佳,朱卫红,刘文斌等. 全科门诊简洁干预联合团队链式管理对血脂异常的干预效果研究[J]. 中国全科医学, 2018, 21(31): 3882-3885. DOI: 10.12114/j.issn.1007-9572.2018.31.022.

References

［1］国家卫生和计划生育委员会疾病预防控制局．中国居民营养与慢性病状况报告（2015年）［M］．北京：人民卫生出版社，2015．
State health and family planning commission disease prevention and control bureau.Report on nutrition and chronic diseases in China（2015）［M］．Beijing：People's Medical Publishing House，2015．
［2］MORAN A，GU D，ZHAO D，et al．Future cardiovascular disease in china：markov model and risk factor scenario projections from the coronary heart disease policy model-China［J］．Circ Cardiovasc Qual Outcomes，2010，3（3）：243-252．DOI：10.1161/CIRCOUTCOMES.109.910711.
［3］WANG F，YE P，HU D，et al．Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China：subgroup analysis of the dyslipidemia international study-China（DYSIS-China）［J］．Atherosclerosis，2014，237（1）：99-105．DOI：10.1016/j.atherosclerosis.2014.08.023．
［4］ZHAO S，WANG Y，MU Y，et al．Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China：results of the dyslipidemia international study（DYSIS）［J］．Atherosclerosis，2014，235（2）：463-469．DOI：10.1016/j.atherosclerosis．2014.05.916.
［5］李向君，王云锋，王美辰，等．北京市某功能社区居民血脂异常患病现况及其影响因素分析［J］.实用心脑肺血管病杂志，2017，25（8）：90-92．DOI：10.3969/j.issn.1008-5971.2017.08.021.
LI X J，WANG Y F，WANG M C，et al．Prevalence of dyslipidemia and influencing factors in a functional community in Beijing［J］．Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease，2017，25（8）：90-92．DOI：10.3969/j.issn.1008-5971.2017.08.021.
［6］中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南（2016年修订版）［J］．中华全科医师杂志，2017，16（1）：14-34．DOI：10.3760/cma.j.issn.1671-7368.2017.01.006.
Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults.Chinese guidelines on prevention and treatment of dyslipidemia in adults（revised edition of 2016）［J］．Chinese Journal of General Practitioners，2017，16（1）：14-34．DOI：10.3760/cma.j.issn.1671-7368.2017.01.006.
［7］KULICK D，LANGER R D，ASHLEY J M，et al．Live well：a practical and effective low-intensity dietary counseling intervention for use in primary care patients with dyslipidemia：a randomized controlled pilot trial［J］．BMC Family Practice，2013，14：59．
［8］刘卡丽，尹朝霞，何坚荣，等．血脂异常社区规范化管理方案的应用与效果评价研究［J］．中国全科医学，2011，14（25）：2857-2860．DOI：10.3969/j.issn.1007-9572.2011.25.008.
LIU K L，YIN Z X，HE J R，et al．Application and evaluation of standardized management plan for dyslipidemia in community［J］．Chinese General Practice，2011，14（25）：2857-2860．DOI：10.3969/j.issn.1007-9572.2011.25.008.
［9］张静，陈佳蕾，张焕军．社区综合干预模式对血脂异常患者的管理效果分析［J］．现代实用医学，2015，27（11）：1438-1441．DOI：10.3969/j.issn.1671-0800.2015.11.021.
ZHANG J，CHEN J L，ZHANG H J.Analysis on the effect of community integrated intervention model on the management of patients with dyslipidemia［J］．Modern Practical Medicine，2015，27（11）：1438-1441．DOI：10.3969/j.issn.1671-0800.2015.11.021.
［10］STONE N J，ROBINSON J G，LICHTENSTEIN A H，et al．2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults：a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines［J］．J Am Coll Cardiol，2014，63（25 Pt B）：2889-2934．DOI：10.1016/j.jacc.2013.11.002.
［11］RABAR S，HARKER M，O'FLYNN N，et al．Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease：summary of updated NICE guidance［J］．BMJ，2014，349：g4356．DOI：10.1136/bmj.g4356.
［12］孟亚星，张小玲，张灿，等．氟伐他汀缓释片治疗血脂异常合并高血压患者的疗效及安全性［J］．安徽医学，2018，39（1）：20-24．DOI：10.3969/j.issn.1000-0399.2018.01.006.MENG Y X，ZHANG X L，ZHANG C，et al．Efficacy and safety of fluvastatin sustained-release tablets in treatment of dyslipidemia and hypertension［J］．Anhui Medical Journal，2018，39（1）：20-24．DOI：10.3969/j.issn.1000-0399.2018.01.006.
［13］中国成人血脂异常防治指南制订联合委员会．中国成人血脂异常防治指南［J］．中华心血管病杂志，2007，35（5）：390-419．DOI：10.3760/j.issn.0253-3758.2007.05.003．
Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults.Chinese guidelines on prevention and treatment of dyslipidemia in adults［J］．Chinese Journal of Cardiology，2007，35（5）：390-419．DOI：10.3760/j.issn.0253-3758.2007.05.003．
［14］李勇，赵水平，叶平，等．中国血脂异常门诊患者调脂治疗一级和二级预防达标现状：DYSIS-China亚组分析［J］．中华心血管病杂志，2016，44（8）：665-670．DOI：10.3760/cma.j.issn.0253-3758.2016.08.006.
LI Y，ZHAO S P，YE P，et al．Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy：DYSIS-China subgroup analysis［J］．Chinese Journal of Cardiology，2016，44（8）：665-670．DOI：10.3760/cma.j.issn.0253-3758.2016.08.006.

[1]	LIANG Xiaoxian, YANG Jin, JIN Juzhen, ZHOU Jing, HU Jin, GAI Yun, DING Xiaoyun, WANG Junhua, WANG Ziyun. Association between Chronotype and Dyslipidemia among Population Aged 40-65 Years [J]. Chinese General Practice, 2023, 26(34): 4277-4282.
[2]	WEN Wen, ZHANG Kainan, CHEN Yulan, LI Yu, ZHANG Xiangyang. Correlation of Metabolic Indexes as Predictors with Obstructive Sleep Apnea [J]. Chinese General Practice, 2023, 26(30): 3740-3747.
[3]	HE Yingmei, JIA Xue, ZHU Guojun, LIU Bing. Effect of Serum Uric Acid Longitudinal Trajectory on New-onset Hypertriglyceridemia: a Prospective Cohort Study [J]. Chinese General Practice, 2023, 26(29): 3636-3639.
[4]	HUANG Qixian, WEN Yanting, HUANG Jun, LI Weibin, XU Yongneng, LIN Xiayi, WANG Haoxiang, WENG Fan, YANG Lianping. Prevalence of Dyslipidemia and Its Influencing Factors among Elderly Community Residents [J]. Chinese General Practice, 2023, 26(28): 3520-3525.
[5]	BIAN Lili, LI Xiaoxiao, DU Xueping, DAI Qinfang, WU Lin, SONG Beibei. Risk Stratification of Atherosclerotic Cardiovascular Disease and Lipid Goal Attainment in Hypertensive Patients Registered in Community [J]. Chinese General Practice, 2023, 26(27): 3388-3391.
[6]	ZHOU Shiyu, CHEN Shaolin, DENG Renli, DAI Mi, LIU Tao, TIAN Kunming. The Association and Predictive Value of Lipid Ratios to Metabolic Syndrome: a Multistage Cross-sectional Study [J]. Chinese General Practice, 2023, 26(21): 2589-2596.
[7]	FENG Shuidong, LI Junyan, DENG Shuxiang, CHEN Limou, CAO Mengyue, TANG Yan, TANG Peng, LIU Jun, SHEN Minxue, YANG Fei. Association between Air Pollutant Exposure and Dyslipidemia in Middle-aged and Elderly People in Mining Areas [J]. Chinese General Practice, 2023, 26(18): 2238-2244.
[8]	CHEN Yijia, QI Shengxiang, DU Jinling, WANG Chenchen, ZHOU Hairong, YE Qing, QIN Zhenzhen, SU Jian, WU Ming, HONG Xin. Predictive Value of Cardiometabolic Index for Metabolically Obese Phenotype in Normal Weight Population [J]. Chinese General Practice, 2023, 26(14): 1716-1725.
[9]	YANG Yi, CONG Huiwen, WANG Lianyuan, YANG Liping, BAO Qihan, WANG Haohua, LI Chengsheng, ZHOU Liwen, DING Zichen, SHI Fuyan, WANG Suzhen. Longitudinal Study on the Risk Factors of Stroke in Check-up Population Based on Bayesian Multivariate Joint Model [J]. Chinese General Practice, 2023, 26(12): 1437-1443.
[10]	LIU Chuanfen, LI Zheng, WU Manyan, CUI Yuxia, SONG Jing, ZHANG Chunying, CHEN Hong. Analysis of Serum Lipid Level and Drug Use in Patients with Acute Myocardial Infarction [J]. Chinese General Practice, 2023, 26(11): 1325-1329.
[11]	Liyuan MA, Zengwu WANG, Jing FAN, Shengshou HU. Epidemiology and Management of Hypertension in China: an Analysis Using Data from the Annual Report on Cardiovascular Health and Diseases in China (2021) [J]. Chinese General Practice, 2022, 25(30): 3715-3720.
[12]	Meixin LI, Xin ZHENG, Xiaoying ZHANG, Xiaoxia DU. Effects of Music Therapy Assisted Anagliptin on Glycolipid Metabolism in Patients with Type 2 Diabetes [J]. Chinese General Practice, 2022, 25(26): 3275-3280.
[13]	Yike JIAO, Li JING, Yuanmeng TIAN, Xinbin HAO, Weizhong WANG, Chengguang SONG, Qun SUN, Lei SHI, Jixu SUN, Xiaoxia AN, Liying XING, Zuosen YANG. Recurrence Status and Combined Risk Factors of Surviving Stroke Patients Aged Over 40 in Urban Areas [J]. Chinese General Practice, 2022, 25(18): 2244-2248.
[14]	Yalin YU, Ruiying GUO, Xueyan ZHANG, Bo DONG. Meta Analysis of the Effect of Resistance Training on Cardiovascular Risk Factors in Middle-aged and Older People [J]. Chinese General Practice, 2022, 25(13): 1651-1658.
[15]	YIN Zhaoxia, LUO Youlia, TAN Siwen, CHEN Yanli, FENG Haixuan, GONG Weijie. Hypertension and Glycemic Control and Associated Factors for Poor Control in Patient Populations at High Risk of Atherosclerotic Cardiovascular Disease in the Community [J]. Chinese General Practice, 2022, 25(10): 1197-1205.